IgG:FcγRIIb Signaling on Mast Cells Blocks Allergic Airway Inflammation.

Area of Science:

• Immunology
• Allergy Research
• Respiratory Medicine

Background:

• Immunoglobulin G (IgG) antibodies can inhibit mast cell activation.
• IgG signaling via FcγRIIb receptor blocks IgE-mediated mast cell degranulation and inflammatory gene expression.
• Previous studies showed IgG inhibits mast cell degranulation and inflammatory transcriptional programs.

Purpose of the Study:

• To investigate if allergen-specific IgG can modulate allergic airway inflammation in vivo.
• To determine the role of FcγRIIb receptor in mediating IgG's protective effects.

Main Methods:

• Mice were sensitized to ovalbumin (OVA) and challenged intranasally.
• Mice were pretreated with allergen-specific IgG.
• FcγRIIb-deficient mice were used to assess receptor dependency.
• Airway inflammation, inflammatory cell recruitment, cytokine/chemokine levels, and airway hyperresponsiveness were measured.

Main Results:

• Allergen-specific IgG pretreatment significantly reduced inflammatory cell (macrophages, eosinophils) recruitment to the lungs.
• Elevated chemokine ligands (CCL2, CCL24) and interleukin-5 in bronchoalveolar lavage fluid were reduced by IgG.
• IgG treatment attenuated allergen-induced production of IgE, IL-4, and IL-13.
• Goblet cell hyperplasia, Muc5ac expression, and airway hyperresponsiveness were suppressed in IgG-treated mice.
• All protective effects of IgG were dependent on FcγRIIb expression on mast cells.

Conclusions:

• Allergen-specific IgG effectively reduces allergen-driven airway inflammation and airway hyperresponsiveness in a mouse model.
• The inhibitory effects of IgG are mediated through the FcγRIIb receptor on mast cells.
• These findings support the therapeutic potential of aeroallergen-specific IgG therapy for allergic diseases.